...
首页> 外文期刊>Biochemical and Biophysical Research Communications >The effects of miR-467b on lipoprotein lipase (LPL) expression, pro-inflammatory cytokine, lipid levels and atherosclerotic lesions in apolipoprotein e knockout mice
【24h】

The effects of miR-467b on lipoprotein lipase (LPL) expression, pro-inflammatory cytokine, lipid levels and atherosclerotic lesions in apolipoprotein e knockout mice

机译:miR-467b对载脂蛋白e基因敲除小鼠脂蛋白脂肪酶(LPL)表达,促炎性细胞因子,脂质水平和动脉粥样硬化病变的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Atherosclerosis is a lipid disorder disease characterized by chronic blood vessel wall inflammation driven by the subendothelial accumulation of macrophages. Studies have shown that lipoprotein lipase (LPL) participates in lipid metabolism, but it is not yet known whether post-transcriptional regulation of LPL gene expression by microRNAs (miRNAs) occurs in vivo. Here, we tested that miR-467b provides protection against atherosclerosis by regulating the target gene LPL which leads to reductions in LPL expression, lipid accumulation, progression of atherosclerosis and production of inflammatory cytokines in apolipoprotein E knockout (apoE-/-) mice. Treatment of apoE-/- mice with intra-peritoneal injection of miR-467b agomir led to decreased blood plasma levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), IL-1β and monocyte chemotactic protein-1 (MCP-1). Using Western blots and real time PCR, we determined that LPL expression in aorta and abdominal cavity macrophages were significantly down-regulated in the miR-467b agomir group. Furthermore, systemic treatment with miR-467b antagomir accelerated the progression of atherosclerosis in the aorta of apoE -/- mice. The present study showed that miR-467b protects apoE -/- mice from atherosclerosis by reducing lipid accumulation and inflammatory cytokine secretion via downregulation of LPL expression. Therefore, targeting miR-467b may offer a promising strategy to treat atherosclerotic vascular disease.
机译:动脉粥样硬化是一种脂质紊乱疾病,其特征在于由巨噬细胞的内皮下积累驱动的慢性血管壁炎症。研究表明脂蛋白脂肪酶(LPL)参与脂质代谢,但是目前还不清楚在体内是否会发生microRNA(miRNA)对LPL基因表达的转录后调控。在这里,我们测试了miR-467b通过调节靶基因LPL提供抗动脉粥样硬化的保护作用,从而导致载脂蛋白E基因敲除(apoE-/-)小鼠的LPL表达降低,脂质蓄积,动脉粥样硬化进展和炎性细胞因子的产生。腹膜内注射miR-467b agomir治疗apoE-/-小鼠导致血浆总胆固醇(TC),甘油三酸酯(TG),低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇的血浆水平降低( HDL-C),肿瘤坏死因子-α(TNF-α),白介素-6(IL-6),IL-1β和单核细胞趋化蛋白-1(MCP-1)。使用蛋白质印迹和实时PCR,我们确定在miR-467b agomir组中主动脉和腹腔巨噬细胞中的LPL表达显着下调。此外,用miR-467b antagomir进行的全身性治疗可加速apoE-/-小鼠主动脉中动脉粥样硬化的发展。本研究表明,miR-467b通过下调LPL表达来减少脂质积累和炎性细胞因子分泌,从而保护apoE-/-小鼠免于动脉粥样硬化。因此,靶向miR-467b可能提供治疗动脉粥样硬化性血管疾病的有前途的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号